Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

European Innovation Council · Finished

EnVena Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg Ulcers

Coordinator
Invera Medical Limited, Ireland
Runs
1 October 2022 to 30 September 2024
Status
Finished
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190175560

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, usually on the inside of the leg that will not heal without specialist treatment. The total costs associated with managing venous disease patients across Europe and the US is €33.4 billion per year, representing 2.5% of total healthcare expenditure.

Most patients are treated with ineffective compression bandaging which does not treat the underlying cause and has an unacceptably high recurrence rate. These bandages are also sent to landfill with a high environmental impactEnVena is the world’s first device to mimic the body’s natural healing response to deliver an effective treatment to venous leg ulcer patients.

Topics

Who is involved

OrganisationCityCountryRole
Invera Medical LimitedDublinIrelandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI